Deepak M. Sahasrabudhe

Deepak M. Sahasrabudhe, M.D. is a Professor in the Department of Medicine (Hematology/Oncology) and joint Professor in the Cancer Center and Department of Urology at the University of Rochester School of Medicine and Dentistry. Board-certified in Internal Medicine, Hematology, and Medical Oncology, he specializes in prostate cancer, bladder cancer, kidney cancer, testicular cancer, melanoma, and rare malignancies including Merkel cell carcinoma and Kaposi's sarcoma.

His educational background includes an MBBS from Topiwala National Medical College (India, 1974), Internal Medicine internship/residency at Albany Medical Center Hospital (1976-1979), and Hematology/Oncology fellowships at UNC Hospitals (1979-1982) and University of Rochester Medical Center (1982-1986).

Dr. Sahasrabudhe's research centers on immuno-oncology and urologic malignancies, with emphasis on overcoming treatment resistance in prostate cancer through novel combinations of hormonal therapies, immunotherapies, and targeted agents. His work bridges laboratory investigations of molecular mechanisms like ARv7 splicing variants and PD-L1 inhibition with clinical applications for genitourinary cancers, maintaining a strong interdisciplinary approach to patient-centered innovation.

Analysis of his 15 most recent publications (2018-2024) reveals dominant themes in prostate cancer therapeutics (7 articles), particularly resistance mechanisms to enzalutamide/abiraterone and biomarker discovery. Significant contributions also appear in bladder cancer (3 articles), testicular cancer survivorship (2 articles), and melanoma (2 articles), with consistent focus on immunotherapy applications and translational research from bench to bedside.

Scientific recognition includes:

• Gitelman Award (2009)

Actively practicing at Wilmot Cancer Center, he collaborates with multidisciplinary teams across oncology, urology, and surgery while maintaining exceptional patient satisfaction (4.9/5 from 503 reviews). His clinical philosophy emphasizes that 'a patient is at the end of every stethoscope, robot, sequencing machine and so on,' reflecting deep commitment to personalized care amidst rapidly evolving cancer technologies.

Though specific grant details aren't provided, his extensive publication record and leadership in multi-institutional studies (e.g., SWOG S0337 trial) indicate substantial research funding and mentorship activities within the hematology/oncology community.